Edwards Lifesciences Corp (EW) Financials
Key financial figures for Edwards Lifesciences Corp (Q3 2026).
Edwards Q3 2026 sales rose 10.5% to $1.7155B (11.2% constant currency) and adjusted EPS was $0.80 versus $0.67 a year ago, and the company raised full-year sales growth, TAVR, TMTT and adjusted EPS guidance. Net sales were $1,715.5M, up 10.5% from $1,553.1M a year ago (11.2% constant currency). Nine-month sales were $5,105.1M, up 13.5%. TAVR sales were $1,241.6M, up 8.0% (8.8% constant currency), slower than Q2's 11.3%. TMTT sales were $209.5M as reported, up 44.3% (45.9% constant currency). Surgical sales were $264.4M, up 2.5%. Adjusted EPS from continuing operations was $0.80 versus $0.67 a year ago, above the $0.71 to $0.77 the company guided in July. GAAP diluted EPS was $0.53 versus $0.50 and included a $220.2M impairment of intangible and long-lived assets in operating income. On the outlook: Full-year 2026: total sales growth about 11.5% (from 10% to 11%), TAVR sales growth 9% to 9.5% (from 8% to 9%), TMTT sales $780M to $790M (from $760M to $780M), adjusted EPS $2.97 to $3.05 (from $2.95 to $3.05); Surgical mid-single-digit growth reaffirmed. Q4 2026: total sales $1.67B to $1.75B and adjusted EPS $0.61 to $0.69. Figures are for Q3 2026, as Edwards Lifesciences Corporation reported them.
- Revenue
- $1.7B
- Net Income
- $308M
- EPS
- $0.53
- Total Assets
- $14.1B
- Operating Cash Flow
- $570M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.7B | $308M | $0.53 | 17.44% | $507M |
| Q2 FY2026 | $1.7B | $242M | $0.42 | 29.84% | $585M |
| Q1 FY2026 | $1.6B | $381M | $0.66 | 31.22% | -$21M |
| Q4 FY2025 | $1.6B | $91M | $0.16 | 23.59% | $354M |
| Q3 FY2025 | $1.6B | $291M | $0.50 | 27.37% | $516M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $6.1B | $1.1B | $1.83 | 26.97% | $1.3B |
| FY2024 | $5.4B | $4.2B | $6.97 | 25.35% | $290M |
| FY2023 | $5.0B | $1.4B | $2.30 | 28.49% | $630M |
Frequently asked questions
What was Edwards Lifesciences Corporation's revenue last quarter?
Edwards Lifesciences Corporation reported revenue of $1.72 billion for Q3 FY2026, up 10.5% from the same period a year earlier.
Is Edwards Lifesciences Corporation profitable?
Yes. Edwards Lifesciences Corporation reported net income of $307.5 million for Q3 FY2026, a net margin of 17.92% on revenue.
How has Edwards Lifesciences Corporation's margin trended?
Operating margin was 17.44% in Q3 FY2026, compared with 27.37% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Edwards Lifesciences Corporation generate?
Edwards Lifesciences Corporation generated free cash flow of $506.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Edwards Lifesciences Corp on SentiSense, with up to forty quarters and twenty fiscal years of history.